Matthew Robinson
Managing Director
Get their honest, personalized take on your startup.
Sign in to pitch Matthew →At a glance
- Full Name
- Matthew Robinson
Background
Public web searches did not verify the supplied stub facts that Matthew Robinson is a Managing Director at ICG, that he uses the email address `[hidden]`, or that he is an angel investor focused on seed rounds. I also did not find a public ICG team page, LinkedIn profile, speaker page, headshot, portfolio list, education history, or biography that could be reliably tied to this specific Matthew Robinson.
The supplied firm-domain context points to ICG, a public global alternative asset manager. ICG describes itself as managing and investing client capital across Structured Capital, Private Equity Secondaries, Private Debt, Credit, and Real Assets, with $126bn in AUM as of 31 March 2026 and 23 worldwide locations. Its London head office is Procession House, 55 Ludgate Hill, London, EC4M 7JW, United Kingdom.
ICG’s public investment materials describe a broad institutional alternatives platform, not an individual angel-investing practice. Its Structured Capital platform provides capital solutions to private companies, including control transactions and minority investments, generally for mid-market and upper-mid-market companies with enterprise values of €100m to €2bn.
Investment Thesis & Focus
- I could not verify a personal investment thesis for Matthew Robinson.
- I could not verify that he invests personally as an angel investor or that his investment stage is seed.
- ICG’s public platform focuses on flexible capital across Structured Capital, Private Equity Secondaries, Private Debt, Credit, and Real Assets.
- ICG’s Structured Capital strategy targets private companies, including control and minority investments, generally in Asia-Pacific, North America, and Western Europe.
- ICG states that its Structured Capital strategy is broadly aimed at “high quality mid-market and upper mid-market private companies” with enterprise values of €100m to €2bn.
Notable Investments
- No verified Matthew Robinson-specific investments were found.
- Mediar Therapeutics — ICG Life Sciences co-led an oversubscribed $76m Series B financing announced on 7 January 2026.
- Navarino — ICG announced a partnership to accelerate the company’s growth on 5 January 2026.
- PSB Academy — ICG announced the sale of PSB Academy to Sun Venture on 12 January 2026.
- SCF — ICG announced completion of its exit from SCF via sale to ABL on 18 December 2025.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.